OSU as Network Lead Academic Participating Site for the NCI NCTN

描述（由申请人提供）：来自俄亥俄州州立大学（OSU）的教师参与科学和管理活动，参与会议，管理多个核心实验室，设计研究，并使用癌症中心资源在所有现有成人NCTN网络组中招募患者，以利用组资源。OSU研究人员开发和领导旨在招募多学科治疗试验患者的研究，以及开发和执行相关科学相关的研究，带来血液恶性肿瘤和实体瘤的特殊专业知识。我们的医学，血液学，外科和放射肿瘤学家，移植者，精神病学家，病理学家，细胞遗传学家，翻译和基础实验室科学家，统计学家，流行病学家，护士，药剂师和临床研究协调员帮助制定临床和基础科学问题，其答案有助于改善患者预后和了解肿瘤生物学。本申请的目标是提供基础设施，以支持OSU作为网络牵头学术参与站点（NLAPS）参与NCI NCTN计划的科学和临床研究活动。我们将利用这些支持来进行有关肿瘤生物学的科学发现，找到更好的治疗方法，提高患者的生活质量，从而改善影响成人的癌症的结果。该综合项目旨在：1）在I期至I期临床试验中研究新的治疗药物及其毒性; 2）根据临床前数据评估新组合的疗效和毒性，以更有效地利用协同组合; 3）开发多模式方法，使用外科，免疫学和放射治疗措施的最佳组合; 4）整合分子遗传学、生物化学、药理学、免疫学和生物统计学方面的专家参与治疗方案的设计和执行; 5）通过发现和教育博士前和博士后学生，护士，专职医疗人员和医生，改善癌症的结果，6）了解和利用肿瘤异质性，以充分利用靶向治疗的价值，7）改善癌症相关症状的管理，8）招募患者参加试验。

DESCRIPTION (provided by applicant): Faculty from The Ohio State University (OSU) are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using cancer center resources to leverage group resources. OSU investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, trans planters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. The goal of this application is to provide the infrastructure to support OSU's participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (NLAPS). We will use the support to make scientific discoveries about tumor biology, find better treatments and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) Investigate new therapeutic agents, and their toxicities in Phase I to 1 clinical trials; 2) Evaluate the efficacy nd toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) Develop multi-modal approaches using surgical, immunological, and radio therapeutic measures in optimal combinations; 4) Integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) Improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) Understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) Improve the management of cancer related symptoms, and 8) enroll patients on trials.